2-Aminoindane
2-Aminoindane is a synthetic stimulant of the aminoindane class and a rigid structural analogue of amphetamine in which the propane chain is cyclized back onto the benzene ring. It first appeared on the research chemical market around 2003 and has been sold as a designer drug. Its effects have been compared to those of benzylpiperazine and methamphetamine, though very little is known about its recreational use profile.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of 2-AI can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The general head space of 2-AI is described by many as one of mental stimulation, increased focus, and euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Visual
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
2-Aminoindane acts as a monoamine releasing agent with selectivity for the norepinephrine transporter (NET) and dopamine transporter (DAT). It partially substitutes for amphetamine in rodent drug discrimination tests.
Pharmacokinetics
Tolerance
Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
Moderate2-Aminoindane is moderately addictive, carries a high potential for abuse, and can cause psychological dependence. Users report a strong urge to take more within a few hours and again the following day. Long-term use can result in cravings if use is stopped suddenly.
Physical
Physical dependence has not been specifically characterized. While withdrawal effects are mentioned in the context of chronic use, available information primarily addresses psychological rather than physical dependence.
Psychosis Risk
Abuse at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Research on similar stimulants suggests 5-15% of users experiencing stimulant-induced psychosis may not fully recover, though antipsychotic medications are effective at resolving acute symptoms.
History & Culture
2-Aminoindane emerged on the research chemical market around 2003, becoming available primarily through online vendors as a designer drug. As an amphetamine analogue with stimulant properties, it attracted interest within the research chemical community despite very limited documentation of its…
Legality
By Country
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 2-Aminoindane article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.